Antimitochondrial antibody-negative primary biliary cirrhosis with secondary Sjogren syndrome: a case report

被引:0
|
作者
Acharya, Suman [1 ]
Shrestha, Suraj [4 ,5 ]
Poddar, Elisha [4 ]
Neupane, Ashru [3 ]
Khadayat, Ramesh [4 ]
Magar, Sagar R. [4 ]
Lamsal, Manoj [2 ]
Pathak, Rahul [2 ]
机构
[1] Tribhuvan Univ Teaching Hosp, Dept Internal Med, Kathmandu, Nepal
[2] Tribhuvan Univ Teaching Hosp, Dept Gastroenterol, Kathmandu, Nepal
[3] Natl Acad Med Sci, Dept Anesthesiol & Intens Care, Kathmandu, Nepal
[4] Inst Med, Maharajgunj Med Campus, Kathmandu, Nepal
[5] Inst Med, Maharajgunj Med Campus, Kathmandu 44600, Nepal
来源
ANNALS OF MEDICINE AND SURGERY | 2023年 / 85卷 / 11期
关键词
AMA-negative; antimitochondrial antibody; primary biliary cirrhosis; Sjogren's syndrome; URSODEOXYCHOLIC ACID; PROGRESSION; MANAGEMENT; DIAGNOSIS;
D O I
10.1097/MS9.0000000000001143
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction and importance:Primary biliary cholangitis (PBC) is a rare immune-mediated liver disease characterized by the destruction of intrahepatic bile ducts and a positive antimitochondrial antibody (AMA), which is considered a serological hallmark for the diagnosis. Rarely, AMA can be absent/nondetectable in a few cases and is referred to as 'AMA-negative'.Case presentation:The authors present such an uncommon case of AMA-negative PBC in a 39-year-female with Sjogren's syndrome who presented with fatigue, pruritus, and dry eyes.Clinical discussion:Previously published studies state that approximately only about 5% of patients with PBC are 'AMA-negative'. For patients negative for AMA, the diagnosis has to be based on typical pathological features of this disease. Once a diagnosis of PBC is established, regardless of whether it is positive or negative for AMAs, ursodeoxycholic acid is a widely accepted treatment.Conclusion:The presence/absence of AMAs is associated with similar clinical, biochemical, and histopathological characteristics in PBC. The identification of AMAs alone should not impact the diagnosis or treatment of PBC.
引用
下载
收藏
页码:5645 / 5648
页数:4
相关论文
共 50 条
  • [1] Antimitochondrial antibody-negative primary biliary cirrhosis
    Mendes, Flavia
    Lindor, Keith D.
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2008, 37 (02) : 479 - +
  • [2] Antimitochondrial Antibody-Negative Primary Biliary Cirrhosis
    Hirschfield, Gideon M.
    Heathcote, E. J.
    CLINICS IN LIVER DISEASE, 2008, 12 (02) : 323 - +
  • [3] Antimitochondrial antibody-negative primary biliary cirrhosis: a subset of primary biliary cirrhosis
    Liu, Bin
    Shi, Xu Hua
    Zhang, Feng Chun
    Zhang, Wen
    Gao, Li Xia
    LIVER INTERNATIONAL, 2008, 28 (02) : 233 - 239
  • [4] ANTIMITOCHONDRIAL ANTIBODY-NEGATIVE PRIMARY BILIARY-CIRRHOSIS
    LACERDA, MA
    LUDWIG, J
    DICKSON, ER
    JORGENSEN, RA
    LINDOR, KD
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1995, 90 (02): : 247 - 249
  • [5] SJOGRENS-SYNDROME WITH ANTIMITOCHONDRIAL ANTIBODY-NEGATIVE PRIMARY BILIARY-CIRRHOSIS - A CASE OF AUTOIMMUNE CHOLANGITIS
    ARCHIMANDRITIS, A
    TJIVRAS, M
    TSIRANTONAKI, M
    HATZIS, G
    DELLADETSIMA, I
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 1995, 20 (03) : 268 - 270
  • [7] PRIMARY AUTOIMMUNE CHOLANGITIS - AN ALTERNATIVE TO ANTIMITOCHONDRIAL ANTIBODY-NEGATIVE PRIMARY BILIARY-CIRRHOSIS
    TAYLOR, SL
    DEAN, PJ
    RIELY, CA
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1994, 18 (01) : 91 - 99
  • [8] The diagnosis of antimitochondrial antibody-negative primary biliary cholangitis
    Ozaslan, Ersan
    Efe, Cumali
    Ozaslan, Nihal Gokbulut
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2016, 40 (05) : 553 - 561
  • [9] Beneficial hepatic effect of troglitazone in a patient with antimitochondrial antibody-negative primary biliary cirrhosis
    Okai, T
    Mouri, H
    Yamaguchi, Y
    Sawabu, N
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (01): : 209 - 210
  • [10] Is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)?
    Gisbert, JP
    Jones, EA
    Pajares, JM
    Moreno-Otero, R
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (01) : 17 - 27